Market Spotlight: Sjögren’s Syndrome
Market Spotlight: Sjögren’s Syndrome
$1,318.00
This Market Spotlight report covers the Sjögren’s syndrome market, comprising key pipeline and marketed drugs, clinical trials, upcoming events, patent information, a 10-year disease prevalence forecast, and licensing and acquisition deals.
Author: Informa Pharma Intelligence
Publisher: Datamonitor Healthcare
- Description
- Contents
This Market Spotlight report covers the Sjögren’s syndrome market, comprising key pipeline and marketed drugs, clinical trials, upcoming events, patent information, a 10-year disease prevalence forecast, and licensing and acquisition deals.
Key Takeaways
- Datamonitor Healthcare estimates that in 2017, there were approximately 2.2 million prevalent cases of primary Sjögren’s syndrome worldwide, and forecasts that number to increase to 2.5 million prevalent cases by 2026.
- Primary Sjögren’s syndrome has a female predominance. Globally, Datamonitor Healthcare estimates that in 2017, 90.4% of cases aged 15 years and over were female.
- Evoxac, a muscarinic agonist specific to M1 receptors, is the only FDA-approved drug for Sjögren’s syndrome. The majority of industry-sponsored drugs in active clinical development for Sjögren’s syndrome are in Phase II, with only one drug in Phase III.
- Therapies in mid-to-late-stage development for Sjögren’s syndrome focus on a wide variety of targets. Pipeline drugs are administered via the oral, intravenous, and subcutaneous routes.
- High-impact upcoming events for drugs in the Sjögren’s syndrome space comprise topline Phase II trial results for GS-9876, and Phase IIa trial results for prezalumab and UCB5857.
- The overall likelihood of approval of a Phase I arthritis asset is 10.8%, and the average probability a drug advances from Phase III is 79.2%. Drugs, on average, take 8.2 years from Phase I to approval, compared to 8.7 years in the overall autoimmune/immunology space.
- There have been only two licensing and asset acquisition deals involving Sjögren’s syndrome drugs during 2013–18. The exclusive licensing and collaboration agreement between Eli Lilly and Hanmi for $690m, regarding the development and commercialization of Hanmi’s oral BTK inhibitor HM71224 for the treatment of autoimmune and other diseases, was the largest deal during this period.
- The distribution of clinical trials across Phase I–IV indicates that the majority of trials for Sjögren’s syndrome have been in the early and mid-phases of development, with 70% of trials in Phase I–II, and only 30% in Phase III–IV.
- The US has a substantial lead in the number of Sjögren’s syndrome clinical trials globally. The UK leads the major EU markets, while Japan has the top spot in Asia.
- Clinical trial activity in the Sjögren’s syndrome space is dominated by completed trials. Novartis has the highest number of completed clinical trials for this condition, with seven trials.
- Bristol-Myers Squibb leads the industry sponsors with the highest number of clinical trials for Sjögren’s syndrome, followed by Novartis.
CONTENTS
5 OVERVIEW
6 KEY TAKEAWAYS
7 DISEASE BACKGROUND
8 TREATMENT
8 Dry eyes
8 Dry mouth
8 Other glandular manifestations
9 Extraglandular manifestations
10 EPIDEMIOLOGY
15 MARKETED DRUGS
17 Approvals by country
19 PIPELINE DRUGS
24 KEY UPCOMING EVENTS
25 PROBABILITY OF SUCCESS
26 LICENSING AND ASSET ACQUISITION DEALS
26 OSE Immunotherapeutics Licenses IL-7 Antagonist To Servier
27 PARENT PATENTS
28 CLINICAL TRIAL LANDSCAPE
29 Sponsors by status
30 Sponsors by phase
32 BIBLIOGRAPHY
32 Prescription information
33 APPENDIX
LIST OF FIGURES
12 Figure 1: Trends in prevalent cases of primary Sjögren’s syndrome, 2017–26
19 Figure 2: Overview of pipeline drugs for Sjögren’s syndrome in the US
19 Figure 3: Pipeline drugs for Sjögren’s syndrome, by company
20 Figure 4: Pipeline drugs for Sjögren’s syndrome, by drug type
20 Figure 5: Pipeline drugs for Sjögren’s syndrome, by classification
24 Figure 6: Key upcoming events in Sjögren’s syndrome
25 Figure 7: Probability of success in the Sjögren’s syndrome pipeline
26 Figure 8: Licensing and asset acquisition deals in Sjögren’s syndrome, 2013–18
27 Figure 9: Parent patents in Sjögren’s syndrome
28 Figure 10: Clinical trials in Sjögren’s syndrome
28 Figure 11: Top 10 drugs for clinical trials in Sjögren’s syndrome
29 Figure 12: Top 10 companies for clinical trials in Sjögren’s syndrome
29 Figure 13: Trial locations in Sjögren’s syndrome
30 Figure 14: Sjögren’s syndrome trials status
31 Figure 15: Sjögren’s syndrome trials sponsors, by phase
LIST OF TABLES
11 Table 1: Prevalent cases of primary Sjögren’s syndrome, 2017–26
13 Table 2: Prevalent cases of primary Sjögren’s syndrome, by gender, 2017
14 Table 3: Prevalence of primary Sjögren’s syndrome, by gender, 2017
16 Table 4: Marketed drugs for Sjögren’s syndrome
18 Table 5: Approvals by country for Sjögren’s syndrome
21 Table 6: Pipeline drugs for Sjögren’s syndrome in the US
© Informa UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
